The FDA updated the emergency use authorization (EUA) for the combined administration of bamlanivimab and etesevimab – two monoclonal antibodies – to include emergency use as a post-exposure prophylaxis (prevention) for COVID-19 patients aged 12 or older who are at high risk of progression to severe COVID-19. These drugs can only be administered as a prophylaxis for COVID-19 if patients are not fully vaccinated or are not expected to mount an adequate immune response to complete COVID-19 vaccination, including for example, immunocompromised patients. Post-exposure prophylaxis is not a substitute for vaccination against COVID-19.
